IRBM Selected for Participation in National Chemical Biology Consortium
4 April 2023 – ROME, ITALY. IRBM, a drug discovery and early development research institute and global contract research organization, announces that it is joining the Chemical Biology Consortium (CBC), the discovery engine of the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program, administered through the Frederick National Laboratory for Cancer Research (FNLCR), a federal national laboratory sponsored by the NCI, part of the National Institutes of Health, and currently operated by Leidos Biomedical Research, Inc. The goal of the program is to help support the translation of novel therapeutic interventions arising from academic, private or government entities into tomorrow’s anticancer therapeutics.
